Bromperidol, a new butyrophenone neuroleptic: a review.
This review compares and contrasts the preclinical pharmacology of bromperidol with another butyrophenone neuroleptic, haloperidol, and the phenothiazine neuroleptic chlorpromazine. Its pharmacokinetics, biotransformation, and safety in several laboratory animal species are also summarized. These preclinical data support its use as an antipsychotic agent and show that it is well absorbed following oral administration with an apparent elimination half-life of approximately 24 h, supporting a once-daily dose regimen. Animal toxicity (including acute- and multiple-dose toxicology and reproductive and mutagenicity studies) show that bromperidol is well tolerated.
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D001667:Binding, Competitive; D001711:Biotransformation; D001921:Brain / Q000378:metabolism; D002746:Chlorpromazine / Q000378:metabolism / Q000494:pharmacology; D004285:Dogs; D005260:Female; D006207:Half-Life; D006220:Haloperidol / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity; D008297:Male; D051379:Mice; D009270:Naloxone / Q000378:metabolism; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D011957:Receptors, Opioid / Q000187:drug effects
D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D011957:Receptors, Opioid; D009270:Naloxone; D006220:Haloperidol; C006820:bromperidol; D002746:Chlorpromazine